Structure of PF-06835919

first-in-class ketohexokinase (KHK) inhibitor

oral candidate in Ph. II for NAFLD/NASH

from frag.-based screening, SBDD, and opt.

J. Med. Chem., Sep. 27, 2020

Pfizer, Cambridge, MA / Groton, CT

PF-06835919 is an oral first-in-class clinical candidate for NAFLD/NASH targeting ketohexokinase (KHK), an enzyme which initiates the metabolism of fructose. The authors describe a very elegant structure-based design campaign to…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.